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Liver biopsyAbstract Background: Chronic hepatitis C is the most common cause of chronic liver disease and
cirrhosis. Egypt is the highest affected country with a prevalence of 22%. In children, seropreva-
lence of HCV is 0.2% in children less than 11 years of age and 0.4% in children equal and more
than 11 years of age.
Aim of the work: The purpose of this study was to assess the value of 1H MRS and DW-MRI as
noninvasive tool in evaluation of activity and ﬁbrosis of hepatic parenchyma in asymptomatic chil-
dren with chronic hepatitis C.
Subjects and methods: Across-section study was conducted over a period of two years, included
thirty children of asymptomatic chronic hepatitis C virus infection (mean age ± SD 14.1
± 2.8 years) and twenty healthy children as controls were included. Abdominal ultrasonography,
percutaneous liver biopsy, MRS and DW-MRI were done to all cases.
Results: The results showed that HCV infection was more common in our males (83.3%).
The results of METAVIR grades showed 29 cases (99.9%) had activity while 17 cases (56.4%)
had ﬁbrosis. The results of MRS and DW-MRI showed signiﬁcant differences between cases and
controls and positive correlations between of the results of 1H MRS with the results of liver biopsy
(METAVIR grades and METAVIR stages).
Conclusion: Early diagnosis of asymptomatic chronic hepatitis C is essential to prevent or delay
end stage chronic parenchymal liver disease. 1H MRS may be a potential noninvasive helpfulepatitis
fﬁcient;
human
740 S.M. Galal et al.diagnostic tool in the assessment of staging and ﬁbrosis of asymptomatic chronic hepatitis C. The
increase in metabolites were correlated with histopathological changes. DW-MRI can be considered
as an effective predictor in the assessment of activity in chronic hepatitis C.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Chronic hepatitis C is the most common cause of chronic liver
disease and cirrhosis (1). Children represent only a small propor-
tion of the hepatitis C virus (HCV) infected population. Never-
theless, a substantial number of children have chronic HCV
infection and are at risk for complications. In children, sero-
prevalence of HCV is 0.2% in children less than 11 years of
age and 0.4% in children equal andmore than 11 years of age (2).
Chronic hepatitis C is marked by the persistence of anti-
HCV antibodies (more than 0.8) with HCV RNA PCR (15–
100.000.000 IU/ml) in the blood for at least 6 months after
onset of acute infection. HCV is self-limiting in only 15–25%
of patients in whom HCV RNA PCR in the serum becomes
undetectable and ALT levels return to normal (2).
Liver biopsy will continue to be the reference standard in
the assessment of the severity of diffuse liver disease until non-
invasively measured markers are validated and clinically
accepted. Several clinical limitations are associated with the
use of liver biopsy. It is an invasive and costly procedure prone
to complications, some minor, such as pain, others severe, the
recorded risk of death being 0.01% (3–5).
MR spectroscopy has been found promising. Phosphorus-
31 MR spectroscopy has been used to study liver metabolism
in vivo (6–8). Lim and colleagues (6) found that in vivo 31P-
MR spectroscopy may be promising in evaluation of the sever-
ity of chronic hepatitis C. An important limitation of 31P-MR
spectroscopy, however, is that it cannot be used to measure
hepatic lipid content, which plays an important pathogenetic
role in the development of the inﬂammation and ﬁbrosis asso-
ciated with liver disease (9–13). Unlike 31P-MR spectroscopy,
1H-MR spectroscopy may be accurate for in vivo quantiﬁca-
tion of liver fat deposition (14,15).
Diffusion-weighted magnetic resonance imaging (DW-
MRI) is a functional MRI technique that takes advantage of
the diffusion properties of water molecules in biological tis-
sues. The microscopic movement of water molecules in biolog-
ical tissues can be measured by apparent diffusion coefﬁcient
(ADC) values derived from DW-MRI. The ADC values were
reported to be inversely related to the degree of severity of
CVH (16,17). In liver ﬁbrosis, extracellular collagen ﬁbers, gly-
cosaminoglycans and proteoglycans may inhibit molecular dif-
fusion of water, which suggest that DWI can be an effective
method for the evaluation of ﬁbrosis. However, considerable
overlap in ADC values between tissues with cirrhosis and with
no to moderate ﬁbrosis was also observed (18).2. Aim of the work
The purpose of this study was to assess the value of 1H MRS
and DW-MRI as noninvasive tools in evaluation of activityand ﬁbrosis of hepatic parenchyma in asymptomatic children
with chronic hepatitis C.
3. Patient and method
3.1. Patients
Thirty (25 males and 5 females) asymptomatic patients known
to have chronic hepatitis C infection were included in this
study that conducted in hepatology unit of Assuit university
children hospital and radiology and pathology departments
of Assuit university hospital from January, 2013 to December,
2014. They were aged 10–18 years and they were not treated by
antiviral therapy. Inclusion criteria were the presence of anti-
hepatitis C virus (HCV) antibodies detected by Enzyme
Immunoassay (EIA) and a serum HCV-RNA by real-time
quantitative HCV RNA PCR (more than 15 IU/ml) for more
than six months. Patients with chronic hepatitis B, cirrhosis,
autoimmune hepatitis and patients received antiviral therapy
or lipid lowering medications as well as patients with co-
infection as Epstein Barr virus, Cytomegalovirus, HIV virus
or fascioliasis or with schistosomiasis were excluded.
Also twenty apparently healthy children of matchable age,
sex, nutritional status and body mass index with nonreactive
anti-HCV antibodies and undetected HCV RNA PCR, anti-
hepatitis B virus or anti-HIV antibodies were taken as controls.
This study was approved by our internal committee of
ethics. All patients and controls gave written informed consent
(see Figs. 1 and 2).
Liver biopsy was performed after spectroscopic and diffu-
sion weighted analysis in all subjects from the right lobe using
a disposable automatic core biopsy 18-Gauge needle (Auto-Vac
biopsy needle, Germany) under conscious sedation by intra-
venous valium and ultrasound guidance. The length of each
liver fragment was about 15 mm length. All liver specimens
were analyzed by an experienced pathologist blinded to results
of MRS and DW-MRI. Histological features were analyzed for
steatosis of increasing fat contents in liver and METAVIR
group scoring system, consists of 5 stages according to the
architectural features of the portal ﬁbrosis: F0 = no ﬁbrosis;
F1 = portal ﬁbrosis without ﬁbrous septa; F2 = portal ﬁbrosis
and few ﬁbrous septa; F3 = numerous septa without cirrhosis;
F4 = cirrhosis. When there was a disparity between 2 adjacent
stages, scores were allocated for the more advanced stage in all
children. The active grades including the intensity of necroin-
ﬂammation were scored as: A0 = no histological activity;
A1 = mild; A2 = moderate; A3 = severe (19,20).
3.2. MR spectroscopy and diffusion weighted imaging
All patients and control were subjected to 1H MR spec-
troscopy and DWI upon Philips 1.5 T (Achieva, Philips
Fig. 1 MR spectroscopy, DWI and pathology pictures for patient with chronic hepatitis C pathologically proved A2 F2; (A) Glx/Lipid
0.23, (B) PME 0.11, (C) Gly/Lipid 0.56, and (D) shows its ADC map measuring about 1.2  103 mm2/s, while (E) shows METAVIR A2
(H and E stain; X 200) and (F) shows METAVIR F2 (Reticulin stain; X 400).
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Fig. 2 MR spectroscopy, DWI and pathology pictures for patient with chronic hepatitis C pathologically proved A1F2; (A and B) Glx/
Lipid 0.15, PME 0.04 and Gly/Lipid 0.32, while (C) ADC map measures about 1.5  103 mm2/s and (D) chronic hepatitis with
METAVIR A1 F2 of TGF-b1-positive sinusoidal cells with moderate distribution and intermediate intensity (via avidin–biotin
immunoperoxidase technique X 400).
742 S.M. Galal et al.Medical Systems, Netherlands). A Q body coil was used for the
radiofrequency-transmitting signal and a body surface coil
for signal receiving. An 8–15 mm length of a cubic shaped
voxel was placed in the right lobe of the liver, avoiding large
blood vessels or biliary structures or GB. Routine T1-
weighted survey images, axial and coronal T2WI were used
for voxel placement. The patient trained to perform calm res-
piration to reduce the line broadening artifacts. The voxel also
located fully inside the deep hepatic parenchyma to preventcontamination by the subcutaneous fat and adjacent struc-
tures. Fully automated frequency determination, power
optimization and shimming phases were performed in the
VOI. A single voxel point-resolved spectroscopy (PRESS)
sequence was used (TR/TE, 1500/38; 256 measurements; 512
sample points yielding an acquisition time of 4:38 min), with-
out water suppression for the assessment of total lipid content
and with water suppression, for the assessment of lipid
composition.
Chronic viral hepatitis C in pediatric age group 743Postprocessing was carried out by using computer software
(Extended MR Workspace 2.6.3.3) incorporated with low-
frequency ﬁltering of residual water signal removal. Various
metabolites on the basis of ﬁndings demonstrated in the nor-
mal liver of humans in studies at known frequencies of glu-
tamine and glutamate complex (Glx) of 2.10–2.49 ppm,
phosphomonoesters (PME) of 3.00–3.21 ppm, and glycogen
and glucose complex (Glyu) of 3.35–3.90 ppm. The peak lipid
frequency was integrated at 1.22–1.62 ppm (see Tables 1–10).
The 1H spectroscopic analysis was performed in patients
and in the control group.Table 1 Demographic data for HCV infection in studied
group and controls.
Cases Controls
Range Mean ± SD Range Mean ± SD
Age 10–18 14.1 ± 2.8 10–18 13.8 ± 2.3
Sex
Male 25 (83.3%) 16 (80.0%)
Female 5 (16.7%) 4 (20.0%)
Table 2 Liver biopsy results of studied group.
Cases (n= 30)
No. %
METAVIR grade
A0 1 3.3
A1 22 73.4
A2 7 23.3
METAVIR stage
F0 13 43.3
F1 5 16.7
F2 12 40.0
Table 3 Comparison between cases and controls according to
metabolites ratio in MR spectroscopy and values of ADC map.
Cases Control P. value
Glx/Lipid 0.169 ± 0.042 0.131 ± 0.011 <0.001**
PME/Lipid 0.061 ± 0.028 0.037 ± 0.007 <0.001**
Glyu/Lipid 0.298 ± 0.098 0.208 ± 0.01 <0.001**
ADC 1.337 ± 0.125 1.57 ± 0.098 <0.001**
** Signiﬁcant.
Table 4 Correlation between MRS and DW-MRI with liver biopsy
Glx/Lipid PME/Lipid
R P. value R P. v
METAVIR grade 0.55 <0.001** 0.52 <0
METAVIR stage 0.30 0.034* 0.49 <0
r correlation coefﬁcient.
* Non signiﬁcant.
** Signiﬁcant.3.3. MRI diffusion
Images were acquired with b-values 0, 300 and 600 s/mm2 gra-
dients. Before DWI was conducted, breath hold, axial T1-
weighted sequence, 2D gradient-echo T1 in-phase and out-
phase, axial respiratory-triggered turbo spin-echo T2-
weighted sequence with fat saturation images were obtained.
All DWIs were acquired in the transverse plane using single-
shot echo-planar spin echo sequences obtained when the sub-
ject was breathing normally. The parameters of the DWMRI
were as follows: TR: 8000 ms; TE: 80 ms; FOV:
30 cm  30 cm; number of excitations: 2; matrix size:
128  128; section thickness: 5 mm; slice number: 72; intersec-
tion gap: none; acquisition time (3 gradients): 96 s. Diffusion-
sensitizing gradients were applied in three orthogonal direc-
tions: frequency-encoding (x), phase-encoding (y) and
section-select (z).
Apparent diffusion coefﬁcient (ADC) measurements were
performed ADC maps automatically after calculating the dif-
fusion difference between each gradient (b 0, 300 and 600)
using 2.6.3.3 Philips Extended Work-space. The ADC values
of the liver parenchyma were obtained in patients and the con-
trol group by taking measurements of equal sized circular
regions of interest (ROIs) in segment 6 of the right lobe of
the liver and summation of b-values using specialized software.
The radiologist who measured the ADC values was blinded to
the histopathological results and clinical histories of the
patients. The size of the ROIs in all patients was equal and
was set at 1 cm2. The ROI was placed far away from visible
vascular structures and at least 1 cm away from the Glissonian
capsule. The ﬁnal ADC for each subject that was used for sta-
tistical analysis was the average of the three ADC values
obtained from the right lobe of the liver.
4. Results
The study including 30 patients with age group ranging from
10 to 18 years as well as 20 control children with the same
age group, in patients group, 25 were males and 5 were females
as well as from 20 controls, 16 were males control and 4 were
females.
In study group, one patient was grade A0 (3.3%) while 13
patients were F0 stage (43.3%). Twenty-two patients (73.4%)
were A1 grade and 5 were F1 (16.7%) stage, also 7 patients
were A2 grade (23.3%) and 12 patients were F2 stage (40%).
There was signiﬁcant difference between the ratio of differ-
ent chosen metabolites in relation to lipid and values of ADC
in diseased group and control group with cut-off values of Glx/
Lipid, PME/Lipid and Glyu/Lipid between normal and dis-
eased child 0.169 ± 0.042, 0.061 ± 0.028 and 0.298 ± 0.098,(METAVIR grade and METAVIR stage) in the study group.
Glyu/Lipid ADC
alue r P. value r P. value
.001** 0.54 <0.001** 0.64 <0.001**
.001** 0.59 <0.001** 0.38 0.007**
Table 5 Correlation between MRS and DW-MRI with different METAVIR grades (A) in study group.
Glx/Lipid PME/Lipid Glyu/Lipid ADC
A0 0.131 ± 0.012 0.037 ± 0.007 0.208 ± 0.009 1.562 ± 0.102
A1 0.167 ± 0.042 0.06 ± 0.024 0.291 ± 0.088 1.341 ± 0.133
A2 0.184 ± 0.04 0.07 ± 0.037 0.334 ± 0.13 1.314 ± 0.107
P1 <0.001** 0.001** 0.001** <0.001**
P2 <0.001** 0.001** <0.001** <0.001**
P3 0.233 0.298 0.188 0.605
P1: Comparison between A0 and A1.
P2: Comparison between A0 and A2.
P3: Comparison between A1 and A2.
** Signiﬁcant.
Table 6 Correlation between MRS and DW-MRI with different METAVIR stages (F) in study group.
Glx/Lipid PME/Lipid Glyu/Lipid ADC
F0 0.146 ± 0.039 0.044 ± 0.018 0.229 ± 0.058 1.47 ± 0.165
F1 0.158 ± 0.019 0.047 ± 0.018 0.254 ± 0.045 1.42 ± 0.11
F2 0.173 ± 0.036 0.074 ± 0.031 0.355 ± 0.108 1.325 ± 0.129
P1 0.519 0.821 0.478 0.502
P2 0.037* <0.001** <0.001** 0.007**
P3 0.444 0.022* 0.011* 0.249
P1: Comparison between F0 and F1.
P2: Comparison between F0 and F2.
P3: Comparison between F1 and F2.
* Non signiﬁcant.
** Signiﬁcant.
Table 7 Sensitivity, speciﬁcity, positive predictive value, negative predictive value and accuracy of 1H MRS components and DW-
MRI in relation to METAVIR grade (A) in study group.
Area under the curve 59% CI for area P. value Cut-oﬀ value Sensitivity Speciﬁcity PPV NPV Accuracy
Glx/Lipid 0.89 0.79–0.98 <0.001** >0.14 79.3 90.5 92.0 76.9 84.3
PME/Lipid 0.75 0.61–0.90 <0.001** >0.049 65.5 100.0 100.0 68.8 80.4
Glyu/Lipid 0.87 0.77–0.98 <0.001** >0.22 72.4 100.0 100.0 73.3 84.3
ADC 0.90 0.82–0.98 <0.001** 61.4 79.3 85.7 85.2 75.0 80.4
** Signiﬁcant.
Table 8 Sensitivity, speciﬁcity, positive predictive value, negative predictive value and accuracy of 1H MRS components and DW-
MRI in relation to METAVIR stage (F) in study group.
Area under the curve 59% CI for area P. value Cutoﬀ value Sensitivity Speciﬁcity PPV NPV Accuracy
Glx/Lipid 0.76 0.62–0.89 <0.001** >0.14 76.5 63.6 52.0 84.6 68.6
PME/Lipid 0.70 0.53–0.88 0.025* >0.049 70.6 78.8 63.2 84.4 76.5
Glyu/Lipid 0.86 0.75–0.96 <0.001** >0.22 82.4 78.8 66.7 90.0 80.4
ADC 0.71 0.56–0.85 0.005** 61.3 58.8 75.8 55.6 78.8 70.6
* Non signiﬁcant.
** Signiﬁcant.
Table 9 Multivariant regression analysis to assess the good
predictors of HCV for activity (A) in studied group.
<beta> P. value
Glx/Lipid 0.162 0.226
PME/Lipid 0.075 0.573
Glyu/Lipid 0.256 0.061
ADC 0.461 <0.001**
** Signiﬁcant.
Table 10 Multivariant regression analysis to assess the good
predictors of HCV for ﬁbrosis (F) in studied group.
<beta> P. value
Glx/Lipid 0.211 0.167
PME/Lipid 0.203 0.183
Glyu/Lipid 0.536 0.001**
ADC 0.201 0.129
** Signiﬁcant.
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Chronic viral hepatitis C in pediatric age group 745respectively. Also, there was a signiﬁcant relation between
ADC values of the HCV group and control group with cut-
off about 1.337 ± 0.125.
There were signiﬁcant positive correlations between MRS
and DW-MRI (ADC value) with the results of liver biopsy
(METAVIR grade and METAVIR stage).
There was signiﬁcant difference between the cut-off values
of different metabolite ratios of grade A0 and both A1 and
A2 on MRS as well as ADC values while no signiﬁcant differ-
ence between grade A1 and A2. This meant that as the activity
of chronic viral hepatitis became higher, all of the metabolite
to lipid ratios increased.
There was signiﬁcant difference between the cut-off values
of different metabolite ratios of stages F0 and F2 on MRS
as well as ADC values while no signiﬁcant difference between
stage F0 and F1 of different metabolite ratios and ADC
values. Signiﬁcant difference between PME/Lipid and Glyu/
Lipid ratios of F1 and F2 stages was also noted while not
for Glx/Lipid ratio and ADC value. This meant that as the
staging of chronic viral hepatitis became higher, the degree
of ﬁbrosis increased, all of the metabolite to lipid ratios
increased.
The sensitivity of Glx/Lipid ratio to predict positive cases
of METAVIR grade (activity) was 79.3% where speciﬁcity
was 90.5%, PPV was 92.0% and NPV was 76.9%. This meant
Glx/Lipid can make good prediction of positive and negative
cases but more for negative than positive. On the other hand
the accuracy of prediction was 84.3% that mean good predic-
tion of cut off value >0.14. That sensitivity of PME/lipid ratio
to predict positive cases of METAVIR grade (activity) was
65.5% where speciﬁcity was 100%, PPV was 100% and NPV
was 68.8%. This meant PME/lipid can make good prediction
of positive and negative cases but more for negative than pos-
itive. On the other hand the accuracy of prediction was 80.4%
that mean good prediction of cut off value >0.049. That sen-
sitivity of Glyu/lipid ratio to predict positive cases of META-
VIR grade (activity) was 72.4% where speciﬁcity was 100%,
PPV was 100% and NPV was 73.3%. This means Glyu/lipid
can make good prediction of positive and negative cases but
more for negative than positive. On the other hand the accu-
racy of prediction was 84.3% that mean good prediction of
cut off value >0.22. That sensitivity of DW-MRI to predict
positive cases of METAVIR grade (activity) was 79.3% where
speciﬁcity was 85.7%, PPV was 85.2% and NPV was 75%.
This means ADC of DW-MRI can make good prediction of
positive and negative cases but more for negative than positive.
On the other hand the accuracy of prediction was 80.4% that
mean good prediction of cut off value 61.4.
The sensitivity of Glx/Lipid ratio to predict positive cases
of METAVIR stage was 76.5% where speciﬁcity was 63.6%,
PPV was 52.0% and NPV was 84.6%. This meant Glx/Lipid
can make good prediction of positive and negative cases but
more for positive than negative. On the other hand the accu-
racy of prediction was 68.6% that mean good prediction of
cut off value >0.14. That sensitivity of PME/lipid ratio to pre-
dict positive cases of METAVIR stage was 70.6% where speci-
ﬁcity was 78.8%, PPV was 63.2% and NPV was 84.4%. This
meant PME/lipid can make good prediction of positive and
negative cases but more for negative than positive. On the
other hand the accuracy of prediction was 76.5% that mean
good prediction of cut off value >0.049. That sensitivity of
Glyu/lipid ratio to predict positive cases of METAVIR stagewas 82.4% where speciﬁcity was 78.8%, PPV was 66.7% and
NPV was 90.0%. This meant Glyu/lipid can make good pre-
diction of positive and negative cases but more for positive
than negative. On the other hand the accuracy of prediction
was 80.4% that mean good prediction of cut off value
>0.22. That sensitivity of DW-MRI to predict positive cases
of METAVIR stage was 58.8% where speciﬁcity was 75.8%,
PPV was 55.6% and NPV was 78.8%. This meant ADC of
DW-MRI can make good prediction of positive and negative
cases but more for negative than positive. On the other hand
the accuracy of prediction was 70.6% that mean good predic-
tion of cut off value 61.3.
The good predictor for HCV activity (A) was ADC of DW-
MRI. The good predictor for HCV staging of ﬁbrosis (F) was
Glyu/lipid ratio of MRS.5. Discussion
Regarding liver biopsy, it is still considered the current stan-
dard of reference for the assessment of liver ﬁbrosis and steato-
sis which is the hepatic manifestation of the metabolic
syndrome and the earliest biomarker for the development of
liver ﬁbrosis. Histological examination is useful in identifying
the underlying cause of liver disease and assessing the necroin-
ﬂammatory grade and the stage of ﬁbrosis (21–23).
Although our cases were clinically asymptomatic, yet 5
cases (16.7%) showed fat droplets in hepatocytes and the
results of METAVIR grade score showed necroinﬂammatory
changes in 29 cases (99.6%) (22 cases had A1 while 7 cases
had A2). Liver inﬂammation is commonly associated with hep-
atocytes necrosis and apoptosis. These forms of liver cell injury
initiate a sequence of events that is independent of the etiolog-
ical basis for the inﬂammation and can result in hepatic ﬁbro-
sis. Apoptotic bodies derived from the damaged hepatocytes
can activate quiescent hepatic stellate cells and Kupffer cells,
and these activated cell populations can in turn promote
inﬂammatory and ﬁbrogenic responses (24).
In our study, the results of METAVIR stage score of liver
biopsy showed ﬁbrosis in 17 cases (56.7%) (5 cases had F1 and
12 cases had F2). Hepatic ﬁbrosis is commonly preceded by
chronic inﬂammation and persistence of this inﬂammation
has been associated with progressive hepatic ﬁbrosis and the
development of cirrhosis (25,26).
In our study, no signiﬁcant complication was encountered,
although, it is invasive with multiple risks and associated with
sampling error due to small sample size and inter-observer
variability was documented by Bravo et al. (22), the histolog-
ical assessment of a needle biopsy specimen is potentially inac-
curate since heterogenic manifestation of hepatic steatosis can
lead to underscoring of the degree of steatosis or to false pos-
itive results (27). As a result of the problems associated with
liver biopsy, a great effort has been done to ﬁnd an effective
noninvasive method of evaluating liver damage (28).
Among the imaging technique, MR spectroscopy (MRS)
enables the noninvasive measurement of biochemical informa-
tion in vivo. The liver is considered an ideal organ for MRS
investigation due to its anatomical location and increased
metabolic demands (29). 1H MRS is considered to be a non-
invasive gold standard method for measuring hepatic fat con-
tent (30). A number of studies were performed to explore the
diagnostic performance of MRS for characterizing hepatic
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the role of MRS for detecting hepatic ﬁbrosis (31).
Our study showed that there were highly signiﬁcant differ-
ences between the studied group and controls in all compo-
nents of 1H MRS (Glx/Lipid, PME/lipid and Glyc/lipid
ratios). Glx indicates glutamine–glutamate complex which is
the most abundant free amino acids in the body including
the liver. It is known to play a regulatory role at the gene
and protein levels in several cell-speciﬁc processes, including
metabolism, cell proliferation, and protein synthesis and
degradation (32). PME indicates phosphomonoester that the
main contributors to PME are phosphorylcholine and phos-
phorylethanolamine which mainly represent intermediates on
the phospholipid biosynthesis pathway. Those MRS signals
were assigned to choline-containing compounds which com-
prise choline, phosphomonoesters such as phosphocholine,
and phosphodiesters such as glycerophosphorylcholine. They
are either cell membrane precursors (choline and phospho-
choline) or cell membrane degradation products (glycerophos-
phorylcholine) (33). Glyc indicates glycogen–glucose complex
hence in liver glycogen is mainly stored as a glucose reservoir
for other tissues (34).
These metabolites are used to express the metabolic proﬁle
changes which occur in diseased liver with HCV infection.
Our results agree with Cho et al. (35) demonstrated that all
of the relative ratios of Glx to lipid, PME to lipid and Glyu
to lipid increased as the stage of chronic hepatitis became
higher. These are the most prominent changes in 1H MR spec-
troscopic features as the stage of chronic hepatitis changed.
Cho et al. (35) explained these results by the following: First,
the amount of lipid in the liver parenchyma actually decreases
as the stage of disease becomes higher. Second, also the relative
amounts of these metabolites (Glx, PME, and Glyu) increase as
the stage of chronic hepatitis becomes higher. This phe-
nomenon is possible when the affected liver shows stromal col-
lapse and ﬁbrosis of many portal triads. Third, 1H MR
spectroscopic features may be directly inﬂuenced by the
increase in ﬁbrotic tissue as the stage of chronic hepatitis
becomes higher. This may be an unknown effect of increased
collagen ﬁbers in the liver parenchyma that modulates 1H
MR spectroscopic expression. Fourth, increased parenchymal
accumulation of metallic substances, such as iron or copper,
may cause local magnetic ﬁeld inhomogeneity that in our study
the high magnetic ﬁeld was used that masks the effects of iron
and copper on the results of 1H MRS.
Also, Cho et al. (35) suggested that the decreasing relative
signal intensity of lipid with chronic hepatitis might be a result
of the combined effect of the various described phenomena.
The results of their study indicate that the ratios of Glx to
lipid, PME to lipid, and Glyu to lipid were signiﬁcantly differ-
ent between various stages of chronic hepatitis. Stanka et al.
(36) reported that the peak levels of Glyu in cases with liver cir-
rhosis were signiﬁcantly different from those in the normal
liver while not in peak levels of Glx. Also Cobbold et al.
(28) showed that the presence of steatosis is associated with
increased rate of progression of ﬁbrosis. Another explanation
for our results, is that virological mechanisms for steatosis
had been proposed, including inhibition of the microsomal
triglyceride transfer protein by HCV core protein and the acti-
vation by cleavage of sterol regulatory binding proteins (37).
Mechanisms of metabolically mediated steatosis in CHC
include increased insulin resistance which is associated withincreased tumor necrosis factor alpha in animal studies (38).
Hepatic total choline is seen to decrease with increasing ﬁbro-
sis (39). In addition, the diseased liver is subjected to oxidative
stress, which in CHC, is associated with the HCV viral load
and inﬂammation (40).
In our study, there were highly signiﬁcant positive correla-
tions between MRS with the results of liver biopsy in the dif-
ferent grades of activity and with the different stages of
ﬁbrosis. This means that as the activity and stage of chronic
viral hepatitis became higher, that is as the degree of ﬁbrosis
increased, all of the metabolite to lipid ratios increased. By
using multivariant regression analysis in our study, the good
predictor for assessing the stage of ﬁbrosis (F) was Glyu/Lipid
ratio. Awad et al. (41) stated that Transient Elastography
(Fibroscan) demonstrated high performance in the detection
of advanced ﬁbrosis and cirrhosis; while TE performance is
less reliable for the detection of early ﬁbrosis stages (F1 and
F2) as compared to more advanced stages of liver ﬁbrosis.
Diffusion-weighted magnetic resonance imaging (DW-
MRI) is a technique that assesses the freedom of diffusion of
water protons in tissues and has been extensively applied for
the early detection of cerebral ischemia. Recent advances have
made it feasible to apply diffusion MRI techniques for abdom-
inal imaging (42).
In our study there was highly signiﬁcant difference between
the studied group and controls in diffusion-weighted magnetic
resonance imaging (DW-MRI) that was assessed by ADC.
This agrees with Onur et al. (43) who stated that ADC values
obtained at the b100 and b600 gradients can be used to distin-
guish between the liver parenchyma of CVH and healthy
subjects.
Also in our study, there was highly signiﬁcant positive cor-
relation between DW-MRI with the results of liver biopsy in
the different grades of activity and different stages of ﬁbrosis.
Sandrasegaran et al. (18) stated that in liver ﬁbrosis, extracel-
lular collagen ﬁbers, glycosaminoglycans and proteoglycans
may inhibit molecular diffusion of water, which suggest that
DWI can be an effective method for the evaluation of ﬁbrosis
in which previously published studies with DWI showed mod-
erate sensitivity and speciﬁcity in distinguishing advanced
ﬁbrosis to cirrhosis (F3 and F4) from lesser degrees of ﬁbrosis.
However, considerable overlap in ADC values between tissues
with cirrhosis and with no to moderate ﬁbrosis was also
observed. However, Onur et al. (43) stated that ADC measure-
ment was not found to be useful for the estimation of the
degree of necroinﬂammation and ﬁbrosis in CVH. But by
using multivariant regression analysis in our study, ADC
was considered an early good predictor for assessing HCV
activity.
In our study, there were some limitations for the use of 1H
MRS and DW-MRI: Respiratory movement can prevent ade-
quate signal acquisition owing to the inconstant position of a
voxel. However, chronic hepatitis is a diffuse parenchymal dis-
ease, and we carefully located the voxel within the liver. Thus,
the minimal change in the location of a voxel was thought to
be acceptable and therefore was not a serious problem.6. Conclusion
We conclude that early diagnosis of asymptomatic chronic
hepatitis C is essential to prevent or delay end stage chronic
Chronic viral hepatitis C in pediatric age group 747parenchymal liver disease. 1H MRS may be a potential nonin-
vasive helpful diagnostic tool in the assessment of staging of
asymptomatic chronic hepatitis C. The increased metabolites
(Glx, PME, Glyu relative to lipid content) in early asymp-
tomatic cases of chronic hepatitis C reﬂect the progression of
liver ﬁbrosis as they were correlated with histopathological
changes. DW-MRI can be considered an effective method in
evaluating liver activity in asymptomatic chronic hepatitis C.
We recommend that 1HMRS can be used as an indicator of
steatosis to assess and to monitor the responsiveness to antivi-
ral therapy in chronic hepatitis C virus infection instead of
liver biopsy.
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